JP4733648B2 - マトリックスメタロプロテイナーゼ阻害剤としての使用のためのチエノ−イミノ酸誘導体 - Google Patents

マトリックスメタロプロテイナーゼ阻害剤としての使用のためのチエノ−イミノ酸誘導体 Download PDF

Info

Publication number
JP4733648B2
JP4733648B2 JP2006550004A JP2006550004A JP4733648B2 JP 4733648 B2 JP4733648 B2 JP 4733648B2 JP 2006550004 A JP2006550004 A JP 2006550004A JP 2006550004 A JP2006550004 A JP 2006550004A JP 4733648 B2 JP4733648 B2 JP 4733648B2
Authority
JP
Japan
Prior art keywords
ring
alkyl
aryl
het ring
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006550004A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007519654A (ja
JP2007519654A5 (cg-RX-API-DMAC7.html
Inventor
マンフレート・シュドック
ハンス・マター
アルミン・ホーフマイスター
マクシム・ラムピーラ
Original Assignee
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング filed Critical サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Publication of JP2007519654A publication Critical patent/JP2007519654A/ja
Publication of JP2007519654A5 publication Critical patent/JP2007519654A5/ja
Application granted granted Critical
Publication of JP4733648B2 publication Critical patent/JP4733648B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2006550004A 2004-01-31 2005-01-18 マトリックスメタロプロテイナーゼ阻害剤としての使用のためのチエノ−イミノ酸誘導体 Expired - Fee Related JP4733648B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004004974A DE102004004974A1 (de) 2004-01-31 2004-01-31 Thieno-Iminosäure-Derivate als Inhibitoren von Matrix-Metalloproteinasen
DE102004004974.2 2004-01-31
PCT/EP2005/000417 WO2005073236A2 (de) 2004-01-31 2005-01-18 Thieno-iminosäure-derivate als inhibitoren von matrix-metalloproteinasen

Publications (3)

Publication Number Publication Date
JP2007519654A JP2007519654A (ja) 2007-07-19
JP2007519654A5 JP2007519654A5 (cg-RX-API-DMAC7.html) 2008-02-28
JP4733648B2 true JP4733648B2 (ja) 2011-07-27

Family

ID=34801393

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006550004A Expired - Fee Related JP4733648B2 (ja) 2004-01-31 2005-01-18 マトリックスメタロプロテイナーゼ阻害剤としての使用のためのチエノ−イミノ酸誘導体

Country Status (5)

Country Link
US (1) US7399770B2 (cg-RX-API-DMAC7.html)
EP (1) EP1723148A2 (cg-RX-API-DMAC7.html)
JP (1) JP4733648B2 (cg-RX-API-DMAC7.html)
DE (1) DE102004004974A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005073236A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10361075A1 (de) * 2003-12-22 2005-07-28 Pac Tech - Packaging Technologies Gmbh Verfahren und Vorichtung zur Trocknung von Schaltungssubstraten
DE102004053982B4 (de) * 2004-11-09 2011-07-21 Koop, Daniel, 25337 Verwendung von Reibhölzern und Verfahren zum Räuchern von Nahrungsmittelprodukten
DE102005015040A1 (de) * 2005-03-31 2006-10-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
CN104193761B (zh) 2009-12-04 2017-10-17 桑诺维恩药品公司 多环化合物及其使用方法
BR112019001407A2 (pt) 2016-07-29 2019-07-09 Sunovion Pharmaceuticals Inc. compostos e composições e usos dos mesmos
SG10202100724UA (en) 2016-07-29 2021-03-30 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
EP3582815A1 (en) 2017-02-16 2019-12-25 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
MX2020000523A (es) 2017-08-02 2020-08-20 Sunovion Pharmaceuticals Inc Compuestos de isocromano y usos de los mismos.
SG11202007823PA (en) 2018-02-16 2020-09-29 Sunovion Pharmaceuticals Inc Salts, crystal forms, and production methods thereof
JP7703449B2 (ja) 2019-03-14 2025-07-07 スミトモ・ファーマ・アメリカ・インコーポレイテッド イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物
KR20230003503A (ko) 2020-04-14 2023-01-06 선오비온 파마슈티컬스 인코포레이티드 신경학적 및 정신의학적 장애의 치료를 위한 (S)-(4,5-디히드로-7H-티에노[2,3-c]피란-7-일)-N-메틸메탄아민

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5294621A (en) * 1992-10-07 1994-03-15 Ortho Pharmaceutical Corporation Thieno tetrahydropyridines useful as class III antiarrhythmic agents
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
AU7205894A (en) 1993-06-08 1995-01-03 Neogenix, Inc. Purified natural and synthetic compounds for the treatment of osteoarthritis
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (en) * 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
TR199800849T2 (xx) * 1995-11-13 1998-07-21 Hoechst Aktiengesellschaft Siklikle heterosiklik N-ikame edilmi� alfa-iminohidroksamla karbon asitleri
FR2748026B1 (fr) * 1996-04-26 1998-06-05 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TR199900429T2 (xx) * 1996-08-28 1999-05-21 The Procter & Gamble Company Spirosiklik metaloproteaz inhibit�rleri.
CA2297988A1 (en) * 1997-08-04 1999-02-11 Amgen Inc. Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
US6770647B2 (en) * 2001-08-17 2004-08-03 Bristol-Myers Squibb Pharma Company Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
AU2003227648A1 (en) * 2002-04-22 2003-11-03 Ibfb Gmbh Substituted pyrimidine-2,4(1h,3h)-diones for use as matrix metalloproteinase (mmp) inhibitors
CN1187332C (zh) * 2002-04-26 2005-02-02 中国科学院上海有机化学研究所 四氢异喹啉羟肟酸磺酰胺类化合物、合成方法及其用途

Also Published As

Publication number Publication date
JP2007519654A (ja) 2007-07-19
DE102004004974A1 (de) 2005-08-18
WO2005073236A3 (de) 2006-01-26
WO2005073236A2 (de) 2005-08-11
US7399770B2 (en) 2008-07-15
US20070093482A1 (en) 2007-04-26
EP1723148A2 (de) 2006-11-22

Similar Documents

Publication Publication Date Title
CN1202156A (zh) 环和杂环N－取代的α－亚氨基异羟肟酸和羧酸
US7399770B2 (en) Thieno-imino acid derivatives for use as matrix metalloproteinase inhibitors
JP4861179B2 (ja) マトリックスメタロプロテイナーゼの阻害剤として使用される二環式イミノ酸誘導体
JP4764009B2 (ja) マトリックスメタロプロテイナーゼ阻害剤として使用するためのイミノ酸誘導体
US20100099663A1 (en) 4-trifluoromethoxyphenoxybenzol-4'-sulfonic acids, method for the production and use thereof in medicaments
US7205315B2 (en) Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases
KR101315788B1 (ko) 매트릭스 메탈로프로테이나제의 억제제로서 사용하기 위한테트라하이드로푸란 유도체
HK1113367B (en) Tetrahydrofurane derivatives for use as inhibitors of matrix metalloproteinases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080110

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20101124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110228

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110329

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110422

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140428

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees